comparemela.com

Latest Breaking News On - Rogers luo - Page 1 : comparemela.com

Nefecon Included in the Reimbursement Drug List of Beijing Puhui Health Insurance Program as a First-in-Disease Therapy for IgA Nephropathy

/PRNewswire/ An imported version of Nefecon (budesonide) delayed release capsule has been added to the 2023 New Reimbursement Drug List of Specialized.

United statesSouth koreaHong kongBoao lechengRogers luoDrug administrationPuhui health insurance programMunicipal medical insurance bureauMunicipal bureau of financial regulationPuhui health insuranceNational reimbursement drug listReimbursement drug listSpecialized medicinesUnited states foodBeijing puhui health insurance programBeijing municipal medical insurance bureau

Everest Medicines to Hold New Corporate Strategy Online Conference Calls

/PRNewswire/ Everest Medicines (HKEX: 1952), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative.

United statesHong kongUnited kingdomRogers luoEverest medicinesChief executive officerIan wooChief financial officerCall informationEnglish sessionRegistration linkMandarin session

China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

/PRNewswire/ Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation.

United statesMarie galayRogers luoExchange commissionChina national medical products administrationEuropean commissionEuropean union member statesCalliditas therapeuticsEverest medicinesDrug evaluationPriority reviewNew drug applicationNasdaq stockholmAmerican depositary sharesNasdaq global select marketPrivate securities litigation reform act

Calliditas Therapeutics: China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

STOCKHOLM, Dec. 30, 2022 /PRNewswire/ Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of

United statesMarie galayRogers luoExchange commissionChina national medical products administrationEuropean commissionEuropean union member statesEverest medicinesDrug evaluationPriority reviewNew drug applicationNasdaq stockholmAmerican depositary sharesNasdaq global select marketPrivate securities litigation reform act

Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Ro

The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in ChinaThe amu.

United statesBrii bioRogers luoTherapeutics beijing co ltdChina resources pharmaceutical groupNational health commission of chinaNational institute of allergyUs national institutes of healthBrii biosciences limited bioChina resources groupChina resources pharmaceutical commercial group co ltdNational medical products administrationTsinghua universityChinaon julyBrii biosciences limitedNational health commission

vimarsana © 2020. All Rights Reserved.